Sunitinib (marketed as Sutent by Pfizer and previously known as SU11248) is an oral small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.
This page contains content from the copyrighted Wikipedia article "Sunitinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
